stoxline Quote Chart Rank Option Currency Glossary
Annovis Bio, Inc. (ANVS)
7.53  0.14 (1.89%)    11-28 14:47
Open: 7.5
High: 8.2399
Volume: 277,858
Pre. Close: 7.39
Low: 7.3
Market Cap: 77(M)
Technical analysis
2023-11-28 2:16:23 PM
Short term     
Mid term     
Targets 6-month :  10.62 1-year :  12.41
Resists First :  9.1 Second :  10.62
Pivot price 6.21
Supports First :  6.82 Second :  5.42
MAs MA(5) :  6.88 MA(20) :  6.24
MA(100) :  10.22 MA(250) :  12.89
MACD MACD :  -0.3 Signal :  -0.6
%K %D K(14,3) :  76.9 D(3) :  77.7
RSI RSI(14): 57.9
52-week High :  23.88 Low :  5.42
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ANVS ] has closed Bollinger Bands are 12.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.01 - 8.04 8.04 - 8.07
Low: 6.65 - 6.68 6.68 - 6.71
Close: 7.34 - 7.39 7.39 - 7.44
Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Headline News

Mon, 27 Nov 2023
Is it Time to Dump Annovis Bio Inc (ANVS) Stock After it Has Risen 26.85% in a Week? - InvestorsObserver

Mon, 27 Nov 2023
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections - Yahoo Finance

Wed, 08 Nov 2023
Annovis Bio Announces Third Quarter 2023 Financial Results and ... - GlobeNewswire

Mon, 30 Oct 2023
Annovis Bio Announces Launch of Proposed Public Offering - Yahoo Finance

Tue, 24 Oct 2023
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference - Yahoo Finance

Thu, 12 Oct 2023
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 10 (M)
Shares Float 7 (M)
Held by Insiders 29.5 (%)
Held by Institutions 8.4 (%)
Shares Short 522 (K)
Shares Short P.Month 338 (K)
Stock Financials
EPS -4.85
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.74
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -124.1 %
Return on Equity (ttm) -227.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -34 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -1.56
PEG Ratio 0
Price to Book value 10.18
Price to Sales 0
Price to Cash Flow -2.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android